

Pending Claims After Entry of Amendment

1. (Twice Amended) A method for introducing a virus into a cell *in vivo*, said method comprising contacting said cell with said virus and a charged compound that facilitates uptake of the virus by the cell, wherein said compound is selected from the group consisting of a charged polysaccharide, polylysine, acyclodextrin, diethylaminoethane, and polyethylene glycol.

2. The method of claim 1, wherein said cell is in a mammal.

3. (Amended) The method of claim 2, wherein said mammal is a human patient.

4. (Amended) The method of claim 1, wherein said virus comprises an exogenous gene encoding a therapeutic product.

5. (Amended) The method of claim 4, wherein said therapeutic product is selected from the group consisting of hormones, vaccine antigens, antisense molecules, ribozymes, growth factors, enzymes, anti-angiogenic polypeptides, and polypeptides that promote cell death.

7. (Amended) The method of claim 1, wherein said virus is selected from the group consisting of Herpes viruses, Dengue viruses, Adeno-associated viruses, Adenoviruses, papillomaviruses, and retroviruses.

8. (Amended) The method of claim 7, wherein said Herpes virus is selected from the group consisting of HSV-1, HSV-2, VZV, CMV, EBV, HHV6, HHV7, and HHV8.

9. (Amended) The method of claim 7, wherein said virus is a lentivirus.
10. (Amended) The method of claim 9, wherein said virus is a human immunodeficiency virus.
13. (Amended) The method of claim 1, wherein said virus is attenuated.
15. (Amended) The method of claim 1, wherein said charged polysaccharide is a glycosaminoglycan.
16. (Amended) The method of claim 1, wherein said charged polysaccharide is a glycosaminoglycan analog.
17. The method of claim 15, wherein said glycosaminoglycan is selected from the group consisting of dermatan sulfate, heparan sulfate, chondroitin sulfate, and keratin sulfate.
18. The method of claim 16, wherein said glycosaminoglycan analog is dextran sulfate.
19. (Amended) The method of claim 1, wherein said charged compound is contacted with said cell prior to said virus.

20. (Amended) The method of claim 1, wherein said charged compound is contacted with said cell concurrently with said virus.

21. The method of claim 1, wherein said cell is a mature muscle cell.

22. The method of claim 3, wherein said cell is a cancer cell.

24. The method of claim 20, wherein said muscle cell is in a patient with a primary myopathy.

25. The method of claim 3, wherein said patient has a condition that can be treated by production of a therapeutic product for secretion into said subject's circulation.

26. (Amended) The method of claim 3, wherein said virus and charged molecule are delivered locally to said patient.

27. (Amended) The method of claim 3, wherein said virus and charged molecule are delivered systemically to said patient.